| Abbott Laboratories |
Abstract
|
|
Heather Cartwright, Taskin Ahmed |
|
| AstraZeneca |
Abstract
|
|
Heather Cartwright, Taskin Ahmed |
|
| Bayer |
Abstract
|
|
Heather Cartwright, Taskin Ahmed |
|
| Bristol-Myers Squibb |
Abstract
|
|
Heather Cartwright, Taskin Ahmed |
|
| Eli Lilly |
Abstract
|
|
Heather Cartwright, Taskin Ahmed |
|
| GlaxoSmithKline |
Abstract
|
|
Heather Cartwright, Taskin Ahmed |
|
| Johnson & Johnson |
Abstract
|
|
Heather Cartwright, Taskin Ahmed |
|
| Merck & Co |
Abstract
|
|
Heather Cartwright, Taskin Ahmed |
|
| Novartis |
Abstract
|
|
Heather Cartwright, Taskin Ahmed |
|
| Pfizer |
Abstract
|
|
Heather Cartwright, Taskin Ahmed |
|
| Sanofi |
Abstract
|
|
Heather Cartwright, Taskin Ahmed |
|
| Roche, GSK and Pfizer Remain the Most Prolific Big Pharma Dealmakers |
Abstract
|
|
Heather Cartwright, Taskin Ahmed |
|